Policy statements
In circumstances when NHS England needs to implement a commissioning policy quickly, a Policy Statement or Urgent Policy Statement will be developed. These policy statements have been through the standard development process for all policies, including evidence review, impact analysis and decision by the Clinical Priorities Advisory Group (CPAG), however they have not been subject to public consultation. Once the policy statement is published, a full clinical commissioning policy may be developed.
Routinely commissioned:
- Active middle ear implants
- Alemtuzumab for treating relapsing-remitting multiple sclerosis – third cycle (all ages)
- Antivirals for adults with recent onset (acute) hepatitis C
- Biologic therapies for the treatment of juvenile idiopathic arthritis
- Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer
- Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
- Flow diverting devices for intracranial aneurysms
- Maternal intravenous immunoglobulin administration for prevention of alloimmune fetal and neonatal haemochromatosis
- Pembrolizumab for drug-resistant gestational trophoblastic neoplasia
- Positron emission tomography – Computed tomography guidelines (all ages)
- Prenatal surgery for open spina bifida
- Retreatment of Chronic Hepatitis C infection in adults with advanced or decompensated cirrhosis
- Rituximab biosimilar for the treatment of myasthenia gravis (adults)
- Rituximab for the treatment of systemic lupus erythematosus in adults
- Stereotactic radiosurgery / radiotherapy for ocular melanoma and pituitary adenoma
- Stereotactic Radiosurgery and Stereotactic Radiotherapy for Primary Non-Germ Cell Pineal Tumours (All Ages)
- Stereotactic Radiosurgery and Stereotactic Radiotherapy for Intracranial Ependymoma (Children)
- Surgical treatment of complex primary cardiac tumours in children
- Teriparatide for osteoporosis in men (adults)
- Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid
Not for routine commissioning:
- Allogenic Mesenchymal Stromal Cell Infusion Therapy for Children with Severe Generalised Recessive Dystrophic Epidermolysis Bullosa
- Arsenic trioxide for the treatment of high risk acute promyelocytic leukaemia
- Cerebellar stimulator implants
- Cerliponase alfa for neuronal ceroid lipofuscinosis Type 2 in children
- Convection enhanced delivery for diffuse intrinsic glioma
- Deep brain stimulation for indications except movement disorders
- Eculizumab in the prevention of recurrence of C3 glomerulopathy post kidney transplant
- Natalizumab-induced progressive multifocal leukoencephalopathy in relation to immune reconstitution inflammatory syndrome in multiple sclerosis
- Osseointegration for transfemoral amputation (adults)
- Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages)
- Proton Beam Therapy for Adult Lymphoma
- Proton Beam Therapy for Head and Neck Cancer in Adults
- Proton Beam Therapy for Hepatocellular Carcinoma
- Proton Beam Therapy for Oesophageal Cancer in Adults
- Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney in adults
- Selective internal radiotherapy (SIRT) (for review from 1 April 2019)
- Sphenopalatine Ganglion Stimulation for Refractory, Chronic Cluster Headache (adults)
- Surgical treatment for women who have undergone female genital mutilation